Pharma Mar SA (PHMMF) AI Stock Analysis

Pharma Mar SA

(Other OTC:PHMMF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong profitability and marginsVery high gross and net margins indicate that Pharma Mar’s approved oncology portfolio has a high-value economics profile. If maintained, this profitability can support reinvestment in research, commercialization and partnerships while providing resilience against moderate cost pressure.

Negative Factors

Inconsistent revenue growthThe latest revenue contraction shows that growth has not yet become consistently durable despite the prior rebound. Uneven sales can limit operating leverage, make commercial planning less predictable and increase dependence on successful product performance or licensing activity.

Pharma Mar SA (PHMMF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.34B
Dividend Yield: 1.52%
Average Volume (3M): 205
Price to Earnings (P/E): 20.7
Beta (1Y): 0.58
Revenue Growth: 23.38%
EPS Growth: 41.53%
Country: US
Employees: 505
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Pharma Mar SA Business Overview & Revenue Model

Company Description

Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with opera...

Pharma Mar SA Earnings Call Summary

Earnings Call Date:Feb 26, 2026(Q4-2025)|% Change Since:-17.17%|Next Earnings Date:Oct 25, 2022

Earnings Call SentimentPositive

The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.

Positive Updates

Strong Top-Line Growth

Total revenues grew 27% year-on-year in 2025, driven by increased sales, royalties and licensing income (sales +20%, royalties +4%, licensing revenues +66%).

Negative Updates

Decline in U.S. Zepzelca Royalties

Zepzelca royalties in the U.S. decreased 12% year-on-year in 2025, driven by a negative FX impact (Euro–USD ~ -7.5%) and the entry of a new competitor.

Company Guidance

PharmaMar guided for continued 2026 top‑line growth driven by a likely European approval for Zepzelca (EMA opinion expected Q1 2026 with some EU launches possible in H2 2026), expecting U.S. and European sales and royalties to rise next year; commercial spend is projected to increase ~30% over the next two years while R&D should remain roughly flat versus 2025 (≈€95m). Key development milestones and timelines include LAGOON topline in H2 2026 (potential second‑line filing in H2 2026 if positive), SaLuDo enrollment completion in H1 2026 with results in H1 2027 (possible approval in 2028), PM54 having reached recommended dose with an IND cleared for an immunotherapy combo and trial start expected H1 2026 (data slated for ESMO Oct 2026), and PM534 expansion planned in H2 2026. This guidance is supported by strong 2025 results—revenues +27% YoY, EBITDA ≈€68m (~5x 2024), net income €75m (+187% YoY), operating cash flow €53m, cash & financial investments €168m and debt roughly stable to 2024—and positive commercial signals such as a 13% QoQ uplift after the October U.S. approval, +31% growth in France, Yondelis raw material sales +20%, U.S. royalties more than doubled vs 2024 and European unit sales +4%.

Pharma Mar SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PHMMF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:ROVI	78Outperform	EUR 3.16B	17.28	27.84%	1.53%	3.21%	39.34%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ES:ATRY	47Neutral	EUR 198.30M	-2.03	-65.08%	―	-53.44%	-296.14%
ES:ORY	45Neutral	EUR 198.99M	-77.82	-2.23%	―	―	53.50%

* Healthcare Sector Average

Performance Comparison

PHMMF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PHMMF	Pharma Mar SA	74.92	-8.13	-9.79%
ES:ROVI	Laboratorios Farmaceuticos Rovi	62.55	3.88	6.61%
ES:ORY	Oryzon Genomics	2.43	-1.07	-30.63%
ES:IKM	1nKemia IUCT Group SA	0.31	0.00	0.00%
ES:ATRY	Atrys Health SA	2.61	-0.63	-19.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pharma Mar SA AI Stock Analysis